SureTrader SureTrader SPDR Advertisement
Home > Boards > US Listed > Medical - Drugs >

Transgenomic Inc. (TBIO)

Add TBIO Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 6/28/2015 12:43:16 PM - Followers: 28 - Board type: Free - Posts Today: 0


Link to coporate website:

Share Structure
Market Value1 $40,142,705 a/o May 10, 2013
Shares Outstanding 88,225,725 a/o Mar 13, 2013
Float Not Available
Authorized Shares 100,000,000 a/o Aug 02, 2011
Par Value 0.01

Wells Fargo Bank Minnesota, N.A.
Shareowner Services
P.O. Box 64854
St. Paul, MN 55164-0854
Phone: 877-602-7611

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offerings include systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Transgenomic offers its WAVE® DHPLC Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification and have broad applicability to genetic research. To date there have been over 1600 systems shipped to more than 30 countries.

Transgenomic's SURVEYOR® Mutation Detection Kits and the SURVEYOR Check-It Kit provide reagents and protocols for the detection of mutations in DNA.

Transgenomic's Cytogenetics offering includes HANABI automated chromosome harvesting systems that improve laboratory productivity with consistent quality compared to manual methods.

Transgenomic Clinical Reference Laboratory provides reference laboratory services specializing in molecular diagnostics including Mitochondrial Disorders, Oncology and Hematology, Molecular Pathology and Inherited Diseases.

Transgenomic Genomic Research Services is a CRO for pharmacogenomic, translational research and clinical trials.

Colorectal Cancer Testing

Very important AMGEN signs collaberation deal with Mgmt:

"Another potential meaningful near-term contributor to the Lab Services segment (as well as to the Diagnostic Tools segment) relates to the recently consummated agreement with Amgen (NasdaqGS:AMGN) whereby the two companies are collaborating on a KRAS an NRAS gene mutation assay kit to screen patients for colorectal cancer.  The RAScan test is currently available for research use only (RUO) in the U.S. (which will run through Lab Svcs) and for clinical use in Europe - which could help accelerate instrument placements (through Menarini) as well as increase consumables sales"

CRC RAScan™ is a new mutation detection test designed to screen for selected KRAS and NRAS mutations (collectively referred to as “RAS mutations”), in patients with metastatic colorectal cancer (mCRC).The identification of these RAS mutations can give physicians important clinical information to help them make better treatment decisions for their mCRC patients.

KRAS and NRAS are part of the RAS family of genes which encode proteins involved in transmitting signals within cells. When Ras proteins are “switched on” by incoming signals, other genes involved in cell growth, differentiation, and survival are activated. Mutations in KRAS, NRAS and other related genes can lead to Ras proteins becoming permanently activated, causing overactive signaling even in the absence of incoming signals, and can lead to the uncontrolled cell growth that characterizes cancer. Mutations that permanently activate Ras proteins are found in ~25% of human tumors and up to 90% of certain cancers. About 40% of colorectal tumors carry KRAS gene mutations and these mutations have been associated with poor response to EGFR antagonists such as cetuximab and panitumumab. Therefore KRAS mutation status can be used to determine whether or not a patient with colorectal cancer will respond to anti-EGFR therapy.

The CRC RAScan test can identify mCRC patients who have RAS mutations at levels that cannot be detected using traditional Sanger Sequencing methods.

CRC RAScan™ for Colorectal Cancer Tumor Testing is available immediately from Transgenomic’s CLIA-certified laboratory in the United States. For more information on this test, click here.

CRC RAScan Mutation Detection Kits will soon be available in the U.S for research use only. CRC RAScan Mutation Detection Kits include the following kits based on Transgenomic's proprietary SURVEYOR® Nuclease technology:

  • KRAS Exon 2
  • KRAS Exons 3 & 4
  • NRAS Exons 2, 3 & 4

Zacks analyst ~ OUR 2013 OUTLOOK~

We've again made some updates to our model.  We now model 2013 revenue of $32.4 million, implying growth of 3% from 2012.  We look for Laboratory Services and Instruments to generate revenue of $20.0 million (+4%) and $12.4 million (+2%), respectively.  We think net income and EPS come in at ($12.7) million and ($0.14).


New Analyses Identify Predictive Biomarkers For Vectibix® (Panitumumab) In Patients With Metastatic Colorectal Cancer

Biomarker Analysis From Phase 3 PRIME ('203) Study and Phase 2 PEAK ('509) Study Link Additional RAS Gene Mutations to Vectibix Clinical Response

THOUSAND OAKS, Calif., May 15, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from three analyses of Vectibix® (panitumumab) in combination with FOLFOX, an oxaliplatin-based chemotherapy regimen, as a first-line treatment for metastatic colorectal cancer (mCRC). These analyses include the description of new predictive biomarkers of clinical response to Vectibix, activating mutations in KRAS (beyond exon 2) and mutations in NRAS, collectively referred to as RAS.

"Amgen helped establish KRAS gene mutation as a biomarker for lack of response to anti-EGFR treatment," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "The identification of new biomarkers may further help to identify appropriate patients with this incurable disease for such treatment."


Contact Information:
Phone: (402) 452-5437

SEC Filings:

Press Releases:

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
#383   yes indeed. TBIO also looking for 7 Full-time Employees: ash111 06/28/15 12:43:16 PM
#382   That is MONSTER NEWS !!! Tstorm 06/27/15 09:15:29 PM
#381   $TBIO charts ver. A $Pistol Pete$ 06/27/15 01:53:58 PM
#380   10Q Total Assets=$35m,liabilities $24m. Assets/Debt ratio= 1.5 (great ash111 06/27/15 06:53:15 AM
#379   6.2m even better.I meant per increased to ash111 06/27/15 06:48:01 AM
#378   I am curious as to where you saw laser777 06/27/15 06:44:02 AM
#377   Wow.with the float and cap so low and ash111 06/27/15 05:17:34 AM
#376   Wow.with the float and cap so low and ash111 06/27/15 05:16:22 AM
#375   TBIO added to Russell Microcap.... laser777 06/26/15 06:23:15 PM
#374   are these current? TBIO Security Details ash111 06/26/15 02:58:11 PM
#373   Here we go folks! Go TBIO!!! Tstorm 06/26/15 01:26:39 PM
#372   NEWS OUT! Tstorm 06/22/15 07:51:56 AM
#371   Classic example, there was 3k shares showing at Tstorm 06/17/15 01:41:34 PM
#370   Yea they sell their shares at the end Tstorm 06/17/15 01:34:33 PM
#369   Seem the shorts have a hold of it, laser777 06/17/15 12:49:10 PM
#368   Shocking how low this is going..... Tstorm 06/17/15 10:52:35 AM
#367   Transgenomic Launches EGFR CLIA Test That Accurately Detects IMPERIAL DRAGON 06/01/15 08:00:41 AM
#366   Big News From Clovis presented Sunday morning at IMPERIAL DRAGON 06/01/15 07:50:27 AM
#365   CANCER diagnostic tests.....PREVENTION FIRST IMPERIAL DRAGON 06/01/15 06:46:26 AM
#364   Should see $4 IMPERIAL DRAGON 05/31/15 10:24:55 PM
#363   True. Pharma always get shorted on news. Always. fink 05/31/15 12:51:49 PM
#362   Picked up 5k IMPERIAL DRAGON 05/29/15 07:47:07 PM
#361   NO ONE'S BUYING $2.6'S IMPERIAL DRAGON 05/29/15 05:25:22 PM
#360   Sell on the news.:-) mh1156 05/29/15 11:05:48 AM
#359   Morning dumpest continues.... Stock Predictor 05/29/15 10:58:33 AM
#358   Convertible notes: On December 31, 2014, we entered crudeoil24 05/29/15 10:38:49 AM
#357   Dumpfest in the morning Stock Predictor 05/29/15 10:35:15 AM
#356   Is this run over?? Or is this a cjwelch1 05/29/15 10:19:13 AM
#355   Lots of fake bids being put up and KingDMC 05/29/15 10:02:28 AM
#354   Nice trade! crudeoil24 05/29/15 09:44:38 AM
#353   That's exactly what happened. I still made a mattp_160 05/29/15 09:43:58 AM
#352   Huge volume already! Grold1387 05/29/15 09:36:51 AM
#351   TBIO will break it's 52 week high of 4.39 crudeoil24 05/29/15 09:36:17 AM
#350   TBIO @ ASCO in Chicago this weekend. Ton crudeoil24 05/29/15 09:33:32 AM
#349   Boom. Thanks for the heads up! KingDMC 05/29/15 09:31:38 AM
#348   TBIO is a great $$$$$ opportunity! crudeoil24 05/29/15 09:30:16 AM
#347   Sometimes on low floats, the MM's knock out crudeoil24 05/29/15 09:11:21 AM
#346   too risky to leave it unattended. I'd rather mattp_160 05/29/15 09:09:00 AM
#345   The MM's will knock out the stop losses. crudeoil24 05/29/15 09:03:14 AM
#344   I got a Chiropractor appointing right at opening mattp_160 05/29/15 08:58:27 AM
#343   Great one - all levels crossed in resisitance logic_guy 05/29/15 08:50:20 AM
#342   News out @ 7:15 EST crudeoil24 05/29/15 08:37:02 AM
#341   how the heck are you so quick to mattp_160 05/29/15 08:35:11 AM
#340   Already double the avg. volume just in P/M. Super_Pop 05/29/15 08:33:31 AM
#339   I bought 20 MINUTES AGO. crudeoil24 05/29/15 08:33:27 AM
#338   Crude, you getting in this one? Float is mattp_160 05/29/15 08:31:48 AM
#337   OMAHA, Neb.--(BUSINESS WIRE)--May 29, 2015-- crudeoil24 05/29/15 08:27:18 AM
#336   Got another premarket runner! Super_Pop 05/29/15 07:29:04 AM
#335   $TBIO recent news/filings stocktrademan 05/16/15 09:05:02 PM
#334   Interesting Article on "Liquid Biopsies." laser777 05/11/15 03:28:08 PM